Epigenetics: Mechanisms, potential roles, and therapeutic strategies in cancer progression

被引:6
作者
Wang, Dong [1 ]
Zhang, Yan [1 ]
Li, Qingbo [1 ]
Li, Yu [1 ]
Li, Wen [1 ]
Zhang, Ao [1 ]
Xu, Jingxuan [1 ]
Meng, Jingyan [2 ]
Tang, Lin [2 ]
Lyu, Shuhua [3 ]
机构
[1] Tianjin Univ Tradit Chinese Med, Grad Sch, Tianjin 301617, Peoples R China
[2] Tianjin Univ Tradit Chinese Med, Coll Tradit Chinese Med, Tianjin 301617, Peoples R China
[3] Tianjin Union Med Ctr, Dept Pathol, Tianjin 300121, Peoples R China
基金
中国国家自然科学基金;
关键词
Cancer; Epigenetics; Gene expression; Heterogeneity; Tumor microenvironment; ACUTE MYELOID-LEUKEMIA; LONG NONCODING RNAS; STEM-LIKE CELLS; BREAST-CANCER; OVARIAN-CANCER; TUMOR; AZACITIDINE; FIBROBLASTS; SUPPRESSOR; EZH2;
D O I
10.1016/j.gendis.2023.04.040
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations or abnormal expression of oncogenes and tumor suppressor genes are known to cause cancer. Recent studies have shown that epigenetic modifications are key drivers of cancer development and progression. Nevertheless, the mechanistic role of epigenetic dysregulation in the tumor microenvironment is not fully understood. Here, we reviewed the role of epigenetic modifications of cancer cells and non-cancer cells in the tumor microenvironment and recent research advances in cancer epigenetic drugs. In addition, we discussed the great potential of epigenetic combination therapies in the clinical treatment of cancer. However, there are still some challenges in the field of cancer epigenetics, such as epigenetic tumor heterogeneity, epigenetic drug heterogeneity, and crosstalk between epigenetics, proteomics, metabolomics, and other omics, which may be the focus and difficulty of cancer treatment in the future. In conclusion, epigenetic modifications in the tumor microenvironment are essential for future epigenetic drug development and the comprehensive treatment of cancer. Epigenetic combination therapy may be a novel strategy for the future clinical treatment of cancer. (c) 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY license (http://creativecommons.org/ licenses/by/4.0/).
引用
收藏
页数:15
相关论文
共 103 条
[1]   Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression [J].
Aleku, Manuela ;
Schulz, Petra ;
Keil, Oliver ;
Santel, Ansgar ;
Schaeper, Ute ;
Dieckhoff, Britta ;
Janke, Oliver ;
Endruschat, Jens ;
Durieux, Birgit ;
Roeder, Nadine ;
Loeffler, Kathrin ;
Lange, Christian ;
Fechtner, Melanie ;
Moepert, Kristin ;
Fisch, Gerald ;
Dames, Sibylle ;
Arnold, Wolfgang ;
Jochims, Karin ;
Giese, Klaus ;
Wiedenmann, Bertram ;
Scholz, Arne ;
Kaufmann, Joerg .
CANCER RESEARCH, 2008, 68 (23) :9788-9798
[2]   Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma [J].
Allegra, Alessandro ;
Casciaro, Marco ;
Barone, Paola ;
Musolino, Caterina ;
Gangemi, Sebastiano .
CANCERS, 2022, 14 (11)
[3]   A Case of Recurrent Ovarian Cancer and Therapy-Related Acute Myeloid Leukemia Treated with Azacitidine [J].
Ando, Kenju ;
Shimomura, Akihiko ;
Nasu, Ryo ;
Nakanishi, Misao ;
Kawamura, Yukino ;
Hangaishi, Akira ;
Oishi, Hajime ;
Shimizu, Chikako .
CASE REPORTS IN ONCOLOGY, 2021, 14 (03) :1847-1852
[4]   Histone Modifications and Cancer [J].
Audia, James E. ;
Campbell, Robert M. .
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2016, 8 (04)
[5]   Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets [J].
Bajbouj, Khuloud ;
Al-Ali, Abeer ;
Ramakrishnan, Rakhee K. ;
Saber-Ayad, Maha ;
Hamid, Qutayba .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
[6]   Exosomal Non-coding RNAs-Mediated Crosstalk in the Tumor Microenvironment [J].
Chen, Qi ;
Li, Yuefeng ;
Liu, Yueqin ;
Xu, Wenlin ;
Zhu, Xiaolan .
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
[7]   Cancer incidence and mortality in China, 2007 [J].
Chen, Wan-qing ;
Zeng, Hong-mei ;
Zheng, Rong-shou ;
Zhang, Si-wei ;
He, Jie .
CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (01) :1-8
[8]   Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome [J].
Chien, Kelly S. ;
Kim, Kunhwa ;
Nogueras-Gonzalez, Graciela M. ;
Borthakur, Gautam ;
Naqvi, Kiran ;
Daver, Naval G. ;
Montalban-Bravo, Guillermo ;
Cortes, Jorge E. ;
DiNardo, Courtney D. ;
Jabbour, Elias ;
Alvarado, Yesid ;
Andreeff, Michael ;
Bose, Prithviraj ;
Jain, Nitin ;
Kadia, Tapan M. ;
Huang, Xuelin ;
Sheppard, Kimberly B. ;
Klingner-Winton, Cheri ;
Pierce, Sherry A. ;
Dong, Xiao Qin ;
Soltysiak, Kelly A. ;
Kantarjian, Hagop M. ;
Garcia-Manero, Guillermo .
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (03) :378-387
[9]   Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma [J].
Cortes, Jose R. ;
Patrone, Christina C. ;
Quinn, Stuart Aidan ;
Gu, Yuhan ;
Sanchez-Martin, Marta ;
Mackey, Adam ;
Cooke, Anisha J. ;
Shih, Bobby B. ;
Laurent, Anouchka P. ;
Trager, Megan H. ;
Ferrando, Adolfo A. ;
Geskin, Larisa J. ;
Palomero, Teresa .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (12) :2908-+
[10]   Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study [J].
Cousin, Sophie ;
Blay, Jean-Yves ;
Garcia, Irene Brana ;
de Bono, Johann S. ;
Le Tourneau, Christophe ;
Moreno, Victor ;
Trigo, Jose ;
Hann, Christine L. ;
Azad, Arun A. ;
Im, Seock-Ah ;
Cassier, Philippe A. ;
French, Christopher A. ;
Italiano, Antoine ;
Keedy, Vicki L. ;
Plummer, Ruth ;
Sablin, Marie-Paule ;
Hemming, Matthew L. ;
Ferron-Brady, Geraldine ;
Wyce, Anastasia ;
Khaled, Ahmed ;
Datta, Antara ;
Foley, Shawn W. ;
McCabe, Michael T. ;
Wu, Yuehui ;
Horner, Thierry ;
Kremer, Brandon E. ;
Dhar, Arindam ;
O'Dwyer, Peter J. ;
Shapiro, Geoffrey I. ;
Piha-Paul, Sarina A. .
INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (06) :993-1006